Oral Cancer News – Page 169 – The Oral Cancer Foundation News Archive

Baseball Great Blames Smokeless Tobacco for Cancer

Source: Dr.Bicuspid.com February 14, 2012 -- Baseball Hall of Fame outfielder Tony Gwynn underwent surgery today in San Diego to remove a cancerous lesion in his mouth, according to an article on ESPN.com. This is the second time in two years that Gwynn has developed a malignant growth in his right cheek. He blames smokeless tobacco for the cancer; he dipped during his entire 20-year career with the San Diego Padres and for 10 years after that as well. Since the 2010 operation, however, Gwynn has not used smokeless tobacco, instead opting for a doctor-approved synthetic dip that he said "tasted awful." But last month, the cancer returned, according to ESPN. Doctors do not believe the cancer has spread outside of Gwynn's salivary gland, Gwynn's wife told ESPN. During the operation, doctors will conduct further biopsies of Gywnn's parotid gland, she said. Gwynn is currently the baseball coach at San Diego State. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2012-02-15T17:22:02-07:00February, 2012|Oral Cancer News|

“Through With Chew 2012”

Source: LeaderAdvisor.com “Through With Chew 2012” is designed to raise awareness about the variety of new smokeless tobacco products (SLT), dangerous especially to young people, not only because the amount of nicotine absorbed from these products is substantially higher than the amount absorbed from a cigarette, but also because of the aggressive marketing of these new products by the tobacco companies. Some of the latest tobacco industry innovations include tobacco dispensed in oral pouches, dissolvable tobacco (orbs) and the electronic cigarette. Aggressive marketing includes the fact that the five largest tobacco manufacturers spent $547.9 million on SLT advertising and promotions in 2008, up from the previous year by 34 percent (www.cdc.gov). A goal of the education campaign this year is to educate parents, teachers, administrators and coaches about these new products, that the packaging often resembles candy packaging, and that they are actually tobacco-containing products. Tobacco industry documents themselves indicate that SLT products are aggressively marketed toward youth, and that the industry has a strategy to progressively move youth from candy or fruit flavored products to more robust varieties for the nicotine dependent user (www.tobaccofreekids.org). Because so many people die per year due to tobacco-related illness, the tobacco companies need to find replacement users for their products. Tobacco use, no matter what form, remains the leading cause of death in this country annually. Just as in cigarettes, the leading cancer-causing agents in SLT are the tobacco-specific nitrosamines, which are formed during the growing, curing, fermenting and aging of tobacco leaves. [...]

Charlotte Parker2012-02-15T10:49:15-07:00February, 2012|Oral Cancer News|

HPV Connected to Oral Cancers Too

Source: Chicago Tribune It's common knowledge that HPV — or human papillomavirus — is linked with cervical cancer, thanks to the controversy over the vaccine. But far fewer people know that this same sexually transmitted viral strain is connected to oral cancers, according to a new study, recently published in the Journal of the American Medical Association. For years, clinicians thought these kinds of cancer — affecting the tongue and tonsil areas — were almost exclusively caused by tobacco use, since they mostly struck heavy smokers and drinkers. But according to Dr. Maura Gillison, an oncologist and researcher at Ohio State University, it's not cigarettes that are the culprit, but oral sex. The good news: Most people with oral HPV will never develop cancer. Dr. Ezra Cohen, a specialist in head, neck, thyroid and salivary gland cancers at the University of Chicago, helped explain what it all means: Q. In general, mouth cancers are increasing? A. Oropharynx cancer is on the rise dramatically. It's gone up 3 percent a year for the last three decades and will surpass all other sites for head and neck cancers. Q. And HPV-positive oral cancers? A. They will surpass cervical cancers within the next three years. It's only relatively recently that we've come to realize the scope of HPV-related cancers. Q. What have we learned from this study? A. Quite a lot, actually. It told us about prevalence — that about 7 percent of adults in the U.S. are infected with oral HPV... and [...]

Charlotte Parker2012-02-15T10:45:22-07:00February, 2012|Oral Cancer News|

HPV a gender-neutral killer

Source: DailyPress.com Socially conservative lawmakers will likely repeal Virginia's requirement that schoolgirls get vaccinated against a sexually transmitted virus called HPV that can, and now will, kill many of them. They're repealing it in the name of sexual abstinence, family values and apple pie. In the name of keeping government out of private health-care decisions — and, yes, they say that with a straight face. A body count doesn't bother them. Virtually all cervical cancer is caused by the human papillomavirus, which infects about 80 percent of sexually active adults by age 40. Most don't even know they have it. But, in some women, the virus mutates cells lining the cervix, turning them into cancerous lesions. About 12,000 women each year are diagnosed with cervical cancer, and 4,000 of them will die of it, according to the National Cancer Institute. This vaccine would prevent nearly all that cancer. All that death. Yet for moral reasons, not medical, the GOP-controlled House voted last month to eliminate the state's 2007 requirement that girls receive the vaccine before enrolling in sixth grade. (The vaccine is most effective before the onset of sexual activity.) The bill now goes to the GOP-controlled Senate, where it's also expected to pass. Lawmakers in Richmond weren't swayed by appeals to conscience, to logic or to medicine. They didn't care that the law already allows parents to decline the vaccine for their child for any reason whatsoever. They even rejected an amendment by a socially conservative colleague, Del. Chris [...]

Charlotte Parker2012-02-15T10:16:31-07:00February, 2012|Oral Cancer News|

Alcohol withdrawal syndrome worsens cancer surgery outcomes

Source: www.oncologyreport.com/ Author: Damian McNamara Patients with head and neck cancers who develop alcohol withdrawal syndrome perioperatively experience significantly more complications after undergoing surgery, a large database analysis indicates. The presence of withdrawal symptoms was associated with a 25% incidence of postoperative complications, compared with 14% among patients who abused alcohol and 7% among those without alcohol abuse, Dr. Dane J. Genther said at the Triological Society’s Combined Sections Meeting. The risk for wound complications was nearly double in this population (odds ratio, 1.9). Dr. Genther, a resident in otolaryngologyhead and neck surgery at Johns Hopkins Hospital in Baltimore, and his associates used ICD-9 codes in the Nationwide Inpatient Sample discharge database to identify more than 92,000 patients who underwent an ablative procedure for head and neck cancer in 2003-2008. The retrospective, cross-sectional study included patients with malignant oral cavity, laryngeal, hypopharyngeal, and oropharyngeal neoplasms. In a multivariate analysis, alcohol withdrawal syndrome was significantly more likely for patients undergoing a major procedure (OR, 2.0) and was significantly associated with Medicare payer status and a need for additional health care following discharge, Dr. Genther said. The researchers found no significant association between alcohol withdrawal syndrome and increased risk for postoperative infections or in-hospital mortality, but there was a significant increase in hospital stay and related costs associated with the syndrome. Having a major procedure and experiencing alcohol withdrawal contributed approximately $15,000 per admission in 2011 U.S. dollars, Dr. Genther said. The findings point to a need for alternatives to current alcohol [...]

Oral Cancer Foundation News Team - A2012-02-14T22:35:07-07:00February, 2012|Oral Cancer News|

IMRT provides better QOL in head and neck cancers

Source: www.oncologyreport.com/ AUthor: Miriam E. Tucker Intensity-modulated radiotherapy is more expensive than 3-D–conformal radiotherapy is and has not been shown to improve standard outcomes in patients with head and neck cancer. But it results in better quality of life. These findings from two studies presented at the Multidisciplinary Head and Neck Cancer Symposium raise the question: Does improved quality of life justify the greater expense of intensity modulated radiotherapy (IMRT), which has been rapidly adopted for the treatment of head and neck cancer? Because IMRT spares surrounding tissues, it reduces the likelihood of developing xerostomia, noted Dr. Nathan C. Sheets, who presented data on billing charges associated with IMRT, compared with 3-D–conformal radiotherapy (CRT). IMRT is reimbursed at a substantially higher level than CRT, however, and it is unclear how to assess this cost relative to other aspects of care in this population, said Dr. Sheets, a radiation oncology resident at the University of North Carolina, Chapel Hill. A separate study presented by Dr. Allen M. Chen compared quality of life in patients who received IMRT vs. CRT. "There’s very little data to suggest IMRT is better than non-IMRT using traditional end points. But the question is: How do you define ‘better’?" said Dr. Chen, director of the radiation oncology residency training program at the University of California, Davis in Sacramento. "IMRT might not particularly involve better cure rates, but it could make a difference in terms of other end points, such as quality of life, which we all know [...]

Oral Cancer Foundation News Team - A2012-02-12T09:20:40-07:00February, 2012|Oral Cancer News|

Head and neck cancer in Canada: trends 1992 to 2007

Source: oto.sagepub.com/ Authors: Johnson-Obaseki et al. Objectives: The objective of this study was to investigate the changes in the epidemiology (incidence, age at diagnosis, and survival) of head and neck cancers (HNCs) in Canada in the past decade. Study Design: Analysis of a national cancer data registry. Setting: All Canadian hospital institutions treating head and neck cancer. Subjects and Methods. Using Canadian Cancer Registry data (1992-2007), the authors categorized HNCs into 3 groups according to their possible association with human papillomavirus (HPV): oropharynx (highly associated), oral cavity (moderate association), and “other” (hypopharynx, larynx, and nasopharynx), which are not HPV related. They calculated age-adjusted incidence, median age at diagnosis, and survival for each category. Results: Oropharynx tumors increased in incidence over the study time period (annual percent change: 1.50% men, 0.8% women), whereas oral cavity tumors decreased (2.10% men, 0.4% women), as did other HNCs (decreased by 3.0% for men and 1.9% for women). The median age at diagnosis for oropharynx cancer decreased by an average of 0.23 years/y. There was no change for oral cavity tumors but an increase for other HNCs of 0.12 years/y. Survival for patients with oropharynx cancer increased by 1.5%/y but was significant for men only. Survival for patients with oral cavity and other HNCs also increased in men only by 0.9%/y and 0.25%/y, respectively. Conclusion: Oropharynx cancer, which is highly correlated with HPV infection, is increasing in incidence in Canada, with a decreasing age at diagnosis and an improvement in survival. This could have implications [...]

Oral Cancer Foundation News Team - A2012-02-12T09:09:35-07:00February, 2012|Oral Cancer News|

Caring for the oral health of patients battling cancer: oral care before cancer treatment

Source: www.dentistryiq.com/ Author: Dennis M. Abbott, D.D.S. Cancer. The New Oxford American Dictionary defines it as “the disease caused by an uncontrolled division of abnormal cells in a part of the body;” but for the millions of people it has touched, cancer is so much more. Cancer is a constant unwanted companion that opens the door to an unchosen journey and demands to be followed. It affects individuals, families and friends. Cancer changes lives. Beyond the emotional toll it imposes, cancer alters the well-being of those it afflicts. Modern treatment regimens given to combat this disease come with a host of deleterious side effects, many of which occur in the mouth. Dentists, dental hygienists and dental auxiliaries are in a unique and necessary position to make a positive impact in the lives of patients battling cancer Making a difference begins with a desire to help and a willingness to take a risk. It is followed by a commitment to learn about the unique oral health care needs of patients engaged in the fight of their lives and put into practice skills that can literally provide comfort and hope. We, as dental professionals, can and should be a part of a comprehensive cancer care team for an ever-growing number of people facing cancer. Dental Oncology Dental oncology is a focus of dentistry dedicated to meeting the unique dental and oral health care needs that arise as a result of cancer therapy. It is an area of oral medicine devoted to improving [...]

Oral Cancer Foundation News Team - A2012-02-12T08:48:16-07:00February, 2012|Oral Cancer News|

Adaptive radiotherapy may benefit patients with head and neck cancer

Source: News-Medical.net Researchers led by a senior investigator at Hofstra-North Shore LIJ School of Medicine and The Feinstein Institute for Medical Research have released initial findings from a first-of-a-kind clinical trial in adaptive radiotherapy (ART) for head and neck cancer. The trial, sponsored by the National Cancer Institute, provides evidence that ART may benefit patients with less technical difficulty than previously believed. The findings of this trial were released online in advance of publication in the International Journal of Radiation Oncology Biology Physics. Physicians commonly use radiotherapy to treat squamous cell carcinoma of the oropharynx (back of throat). Current standard-of-care treatment is called intensity-modulated radiotherapy, or IMRT. IMRT allows physicians to "sculpt" radiation to fit the anatomy of individual patients. Although appealing, this technique has a crucial Achilles' heel - it is based entirely on a CT or MRI scan taken before actual treatment begins. Since a typical course of radiation treatment for oropharynx cancer lasts 6-7 weeks, standard IMRT cannot compensate for common changes that take place in a patient's body during this time, such as weight loss, shrinkage of tumor, or gradual movement of normal tissues. Recent work suggests that the inability of standard IMRT to keep up with these changes may lead to unanticipated toxicity, or potentially worse, missing of tumor. For this new trial, which was conducted at the University of Texas M.D. Anderson Cancer Center, investigators started patients on standard IMRT. They then took CT scans while patients were lying in the radiation treatment room [...]

Charlotte Parker2012-02-10T10:40:11-07:00February, 2012|Oral Cancer News|

Cisplatin Aids Survival of High-Risk Head and Neck Cancer

Source: Oncology Report Adding chemotherapy to radiotherapy improved 10-year survival of resectable head and neck carcinomas among high-risk patients who had microscopically involved resection margins and/or extracapsular spread of disease – but not in high-risk patients who only had tumor in multiple lymph nodes. The findings come from a long-term update and unplanned subset analysis of 410 evaluable patients from the RTOG (Radiation Therapy Oncology Group) 9501 phase III study, which previously showed no overall survival advantage from the addition of cisplatin chemotherapy to radiation. The new data are "good news," according to lead author Dr. Jay Cooper, director of Maimonides Cancer Center in Brooklyn, N.Y. "We now can eradicate some advanced head and neck tumors that we couldn’t before by adding chemotherapy to radiation therapy. At the same time, we can spare other patients who would not do better with the addition of chemotherapy from its side effects," he said at a head and neck cancer symposium sponsored by the American Society for Radiation Therapy. The RTOG 9501 study randomized 459 patients with high-risk, resected head and neck cancers to receive either radiation therapy of 60 Gy in 6 weeks (RT), or identical radiotherapy plus cisplatin at 100 mg/m2 IV on days 1, 22, and 43 (RT+CT). When reported at a median follow-up of 45.9 months, the locoregional control rate was significantly higher in the combined-therapy group than in the group given radiotherapy alone (hazard ratio for locoregional recurrence, 0.61); disease-free survival was significantly longer with combined therapy (HR [...]

Charlotte Parker2012-02-08T10:06:10-07:00February, 2012|Oral Cancer News|